Treatment of chronic hepatitis C in haemophilia patients

Haemophilia

Volumn 6, Issue 6, 2000, Pages 605-613

  Meijer, K ^a   Smid, W M ^a   Van Der Meer, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; BLOOD CLOTTING FACTOR 8 INHIBITOR; HEPATITIS B SURFACE ANTIGEN; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIBODY DETECTION; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LAPAROSCOPY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; MONOTHERAPY; MORTALITY; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS TRANSMISSION;

ADULT; ANTIVIRAL AGENTS; BLOOD TRANSFUSION; HEATING; HEMOPHILIA A; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; TIME FACTORS;

EID: 0033670670     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00398.x     Document Type: Review

References (79)

1. The prevalence of hepatitis C virus infection in the United States 1988 through 1994
2. Variability of hepatitis C virus
3. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients
4. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients
5. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: Effects of prophylactic immune serum globulin
6. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates
7. Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia
8. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates
9. Hepatitis C antibody and chronic liver disease in haemophilia
10. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels
11. Prevalence of hepatitis C antibody in a cohort of hemophilia patients
12. Antibodies to hepatitis C virus in haemophilia
13. Antibodies to hepatitis C virus in haemophilia
14. A multicenter study of viral hepatitis in a United States hemophilic population
15. Hepatitis C infection and viremia in Dutch hemophilia patients
16. The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs
17. Persistent hepatitis C virus RNA replication in haemophiliacs: Role of co-infection with human immunodeficiency virus
18. Anti-HCV seroreversion in HIV-negative haemophiliacs
19. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV 'seroreversion'
20. The low risk of hepatitis C virus transmission among sexual partners of hepatitic C-infected hemophilic males: An international, multicenter study
21. Search for intrafamilial transmission of hepatitis C virus in hemophilia patients
22. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C. A comparison between immunocompetent and immunocompromised patients
23. Natural history of liver fibrosis progression in patients with chronic hepatitis C
24. Natural history of hepatitis C in HIV negative patients with congenital coagulation disorders
25. Investigation of chronic hepatitis C infection in individuals with haemophilia
26. Liver biopsy for haemophilic patients with chronic HCV infection
27. Investigation of chronic hepatitis C infection in individuals with haemophilia: Assessment of invasive and non-invasive methods
28. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus
29. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus
30. Natural history of hepatitic C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus
31. The progression of HCV-associated liver disease in a cohort of haemophilic patients
32. The natural history of chronic hepatitis C in haemophiliacs
33. Hepatocellular carcinoma in hemophilia
34. Hepatocellular carcinoma in UK haemophiliacs
35. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
36. Mortality in patients with hemophilia
37. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease
38. HCV RNA levels and HIV infection: Evidence for a viral interaction in haemophilia patients
39. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
40. Interaction of hepatitis B and hepatitis C infection in haemophilia
41. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs
42. Chronic hepatitis C virus infection in haemophilic patients: Clinical significance of viral genotype
43. Heterogeneity of hepatitis C virus genotypes in hemophilia: Relationship with chronic liver disease
44. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C
45. Panel statement on the management of hepatitis C
46. European Association for the Study of the Liver EASL international consensus conference on hepatitis C
47. Guidelines on the diagnosis and management of chronic liver disease in haemophilia
48. Interferon treatment for chronic hepatitis C infection in haemophiliacs-influence of virus load, genotype, and liver pathology on response
49. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment
50. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan
51. Long term treatment of chronic hepatitic C with interferon alfa-2b: Disappearance of HCV-RNA in a pilot study of eight haemophilia patients
52. Effect and side-effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C
53. High-dose and long-term treatment of α interferon in hemophilic patients with chronic C virus hepatitis
54. A randomized controlled trial of recombinant interferon-α in chronic hepatitis C in hemophiliacs
55. Interferon alfa for chronic hepatitis C in haemophiliacs
56. Alpha interferon for hepatitis C virus infection in haemophilic patients
57. A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C
58. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
59. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials
60. Interferon-α treatment and formation of factor VIII antibodies
61. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A
62. Acquired factor VIII inhibitor associated with chronic interferon-α therapy
63. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C
64. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
65. Long-term course of interferon-treated chronic hepatitis C
66. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
67. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
68. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis
69. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic Hepatitis C osaka hepatocellular carcinoma prevention study group
70. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
71. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
72. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
73. Liver transplantation in hemophilia A
74. Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B
75. Orthotopic liver transplantation in a patient with combined hemophilia A and B
76. Liver transplantation for haemophiliacs with hepatitis C cirrhosis
77. Outcome of orthotopic liver transplantation in patients with haemophilia
78. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C